Zymeworks Inc.
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
About
CEO
Mr. Kenneth H. Galbraith C.A.
Employees
294
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNGS
Address
108 Patriot Drive, Middletown, DE 19709, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 29, 2025 | — | — | — | — |
| Jul 30, 2025 | — | — | — | — |
| May 1, 2025 | — | — | — | — |
| Mar 4, 2025 | 0.01 | — | — | — |
| Nov 1, 2024 | -0.40 | -0.39 | 0.01 | -2.50% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 3 | — | 7 |
| Average estimate | — | -0.38 | — | -1.74 |
| Low estimate | — | -0.59 | — | -2.22 |
| High estimate | — | -0.23 | — | -1.03 |
| Last year EPS | — | -0.42 | — | -1.44 |
[stock_revenue_estimate]
Growth estimates
Current qtr
53.900%
Next qtr. (Mar 2025)
8.730%
Current year
16.120%
Next year (Dec 2025)
-20.780%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 76.01M | 412.48M | 18.36M | 38.95M | 29.54M |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating expense | |||||
| Research & development | 143.62M | 208.60M | 137.43M | 171.20M | 117.37M |
| Selling general and admin | 70.40M | 73.40M | 29.31M | 55.20M | 62.70M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -138.01M | 130.49M | -148.39M | -187.45M | -150.52M |
| Non operating interest income | |||||
| Income | 19.71M | 3.60M | 1.35M | 5.70M | 5.88M |
| Expense | — | — | — | — | — |
| Other income expense | -894,000 | 1.11M | 900,624 | 1.65M | -1.36M |
| Pretax income | -119.24M | 135.23M | -146.11M | -180.12M | -146.02M |
| Tax provision | -568,000 | 10.89M | -355,020 | 429,000 | -582,000 |
| Net income | -118.67M | 124.34M | -145.75M | -180.55M | -145.44M |
| Basic EPS | -1.72 | 1.91 | -4.11 | -3.58 | -3.83 |
| Diluted EPS | -1.72 | 1.90 | -4.61 | -3.58 | -3.83 |
| Basic average shares | 68.86M | 65.19M | 51.55M | 50.38M | 38.02M |
| Diluted average shares | 68.86M | 65.19M | 51.55M | 50.38M | 38.02M |
| EBITDA | -119.52M | 141.34M | -142.61M | -178.86M | -141.86M |
| Net income from continuing op. | -118.67M | 124.34M | -145.75M | -180.55M | -145.44M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | 231,000 | 28.53M | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 580.88M | 648.73M | 267.73M | 538.38M | 368.21M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 157.56M | 400.91M | 138.89M | 242.04M | 128.45M |
| Other short term investments | 216.77M | 91.32M | 34.91M | 184.32M | 170.45M |
| Accounts receivable | 19.48M | 33.40M | 10.74M | 15.29M | 2.19M |
| Other receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Prepaid assets | — | — | 13.76M | 13.43M | 10.74M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 19.12M | 19.07M | 20.00M | 13.43M | 10.74M |
| Non current assets | |||||
| Properties | 29.50M | 32.64M | 24.30M | 12.71M | 12.03M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 7.58M | 7.28M | 4.24M | 5.22M | 4.42M |
| Construction in progress | 122,000 | 76,000 | 9.12M | 964,000 | 915,000 |
| Leases | 20.99M | 20.96M | 6.26M | 9.05M | 6.37M |
| Accumulated depreciation | -20.66M | -13.30M | -9.67M | -10.33M | -7.23M |
| Goodwill | 49.32M | 50.42M | 31.30M | 46.96M | 47.72M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 25.28M | 26.38M | 14.77M | 22.93M | 23.69M |
| Investments and advances | 82.15M | 886,000 | 609,590 | 25.92M | — |
| Other non current assets | 3.72M | 1.36M | 2.95M | 2.53M | 1.87M |
| Total liabilities | 116.07M | 155.77M | 96.35M | 128.45M | 122.52M |
| Current liabilities | |||||
| Accounts payable | 6.21M | 7.86M | 3.56M | 6.24M | 5.35M |
| Accrued expenses | 30.37M | 47.16M | 35.80M | 26.82M | 24.49M |
| Short term debt | 4.26M | 3.32M | 901,312 | 2.71M | 1.28M |
| Deferred revenue | 3.70M | 2.35M | — | — | — |
| Tax payable | 1.81M | 17.08M | — | — | — |
| Pensions | 6.15M | 14.37M | 2.30M | 9.44M | 5.01M |
| Other current liabilities | 2.53M | 1.64M | 5.33M | 39.30M | 45.58M |
| Non current liabilities | |||||
| Long term debt | 22.46M | 24.79M | 21.34M | 5.93M | 5.65M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | 3.30M | 1.79M | 1.08M | 1.18M | 408,000 |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 1.61M | 2.98M | 1.82M | 2.74M | 978,000 |
| Shareholders equity | |||||
| Common stock | 1.01B | 906.76M | 509.93M | 724.22M | 450.21M |
| Retained earnings | -677.44M | -558.76M | -469.99M | -471.26M | -290.71M |
| Other shareholders equity | -6.60M | -6.66M | -4.58M | -6.66M | -6.66M |
| Total shareholders equity | 464.81M | 492.96M | 171.38M | 409.92M | 245.68M |
| Additional paid in capital | 142.27M | 151.61M | 136.03M | 163.62M | 92.84M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||
| Net Income | -118.67M | 124.34M | -145.75M | -180.55M | -145.44M | -36.56M | -10.41M | -33.81M | -19.17M | -12.94M |
| Depreciation | 17.31M | 12.00M | 6.59M | 10.28M | 7.33M | 3.63M | 2.74M | 1.03M | 494,000 | 412,000 |
| Deferred Taxes | -757,000 | 1.94M | -655,687 | 266,000 | -726,000 | -17,000 | 15,000 | -5.51M | 16,000 | — |
| Stock-Based Compensation | 8.10M | 4.02M | 7.40M | 29.12M | 49.00M | 13.44M | 3.43M | 4.29M | 1.39M | 574,000 |
| Other Non-Cash Items | 630,000 | -250,000 | 146,549 | 89,000 | 271,000 | 237,000 | 718,000 | 576,000 | — | 293,000 |
| Accounts Receivable | 13.92M | -17.51M | -183,014 | -13.11M | -1.83M | -119,000 | 2.41M | -1.37M | 297,000 | -595,000 |
| Accounts Payable | -44.77M | 26.48M | 11.34M | 7.62M | 21.57M | 3.68M | -358,000 | 1.93M | 2.42M | -1.74M |
| Other Assets & Liabilities | 36,000 | -3.74M | -17,888 | -1.14M | -4.33M | 36.47M | — | — | -7.52M | 7.00M |
| Operating Cash Flow | -124.20M | 147.28M | -121.13M | -147.43M | -74.15M | 20.77M | -1.45M | -32.86M | -22.07M | -7.00M |
| Investing Activities | ||||||||||
| Capital Expenditures | -2.47M | -8.15M | -8.53M | -4.31M | -6.32M | -803,000 | -2.02M | -4.43M | -626,000 | -80,000 |
| Net Intangibles | -1.60M | -4.98M | -606,150 | -1.96M | -7.56M | -2.62M | -1.11M | -1.04M | -227,000 | -201,000 |
| Net Acquisitions | — | — | — | — | — | — | — | — | -4.04M | — |
| Purchase of Investments | -553.25M | -113.01M | -24.14M | -50.50M | -11.71M | -105.63M | -27.77M | — | — | — |
| Sale of Investments | 350.07M | 72.28M | 132.76M | 13.33M | — | — | — | — | — | — |
| Investing Cash Flow | -205.65M | -48.87M | 100.09M | -41.49M | -18.04M | -106.43M | -29.78M | -4.35M | -4.66M | -80,000 |
| Financing Activities | ||||||||||
| Long-Term Debt Issuance | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | -21,000 | -14,000 | -11,696 | -41,000 | -16,000 | -11,000 | -7.82M | -7,000 | -4,000 | -9,000 |
| Other Financing Charges | -53,000 | -596,000 | -323,371 | -113,000 | -650,000 | -225,000 | — | 5.91M | -360,000 | — |
| Financing Cash Flow | 76.02M | 106.92M | -335,067 | 300.76M | 187.57M | 90.52M | 47.97M | 64.76M | 1.39M | 46.33M |
| Other Cash Details | ||||||||||
| End Cash Position | 157.56M | 400.91M | 138.89M | 242.04M | 128.45M | 42.21M | 35.95M | 16.44M | 11.52M | 46.84M |
| Income Tax Paid | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -122.38M | 130.98M | -141.55M | -157.67M | -95.73M | 20.76M | -2.90M | -40.71M | -23.02M | -7.30M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 2,236,826 | 33.44M | 3.55% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 1,600,472 | 23.93M | 2.54% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 572,900 | 8.56M | 0.91% |
| iShares Russell 2000 Value ETF | Nov 30, 2024 | 542,633 | 8.11M | 0.86% |
| iShares Biotechnology ETF | Nov 30, 2024 | 487,633 | 7.29M | 0.77% |
| Bridgeway Fds Inc-Omni Small Cap Value Fund | Sep 30, 2024 | 406,900 | 6.08M | 0.65% |
| EA Series Trust-EA Bridgeway Omni Small-Cap Value ETF | Sep 30, 2024 | 335,026 | 5.01M | 0.53% |
| Vanguard Russell 2000 Index Fund | Nov 30, 2024 | 261,870 | 3.91M | 0.42% |
| Dimensional ETF Tr-Dimensional U.S. Core Equity 2 ETF | Oct 31, 2024 | 170,131 | 2.54M | 0.27% |
| Federated Hermes MDT Small Cap Core Fund | Oct 31, 2024 | 171,954 | 2.57M | 0.27% |
Article
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences:
Jan 30, 2025
Article
3 Biotech Stocks With Notable Insider Buying
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners.
Jan 22, 2025
Article
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
VANCOUVER, British Columbia, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today provided an update on key strategic priorities for 2025 and 2026.
Jan 8, 2025
